West Virginia Office
of Laboratory Services
167 11th Ave
South Charleston, WV 25303
U.S. Food and Drug Administration (FDA) recently clarified that when it grants
an Emergency Use Authorization (EUA) for a point-of-care test, that test is
deemed to be CLIA-waived. For the duration of the national emergency
declaration for COVID-19, such tests can be performed in any patient care
setting that operates under a CLIA Certificate of Waiver or
Certificate of Compliance/Certificate of Accreditation.
addition, FDA clarified that tests for SARS-CoV-2 that are offered prior to or
without an EUA have not been reviewed by FDA, are not FDA authorized, and have
not received a CLIA categorization. Thus, those tests are
considered high complexity by default until they receive an EUA or other FDA
approval that indicates they may be performed as moderate complexity or waived
list of tests with an EUA, visit https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations.
For a list of serology assays in
which the manufacturer has notified FDA that it will be distributing for use,
but has not sought an EUA, visit https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-diagnostic-testing-sars-cov-2. The list is currently
in the last question of the first block of Q&A on the page. These
are the tests that default to high complexity and may only be used in the
CMS CLIA Testing Requirments for SARS-CoV-2 [NEW]
Please do not hesitate to contact
us with any questions you have regarding SARS-CoV-2 (COVID-19) testing at 304-558-3530 or by email at firstname.lastname@example.org.